Seed Tx
1 known investors
SEED Therapeutics develops de novo molecular glue degraders for targeted protein degradation, using its RITE3 platform to match E3 ligases with disease-causing target proteins. Its lead RBM39 degrader (ST-01156) is in Phase 1 trials for Ewing sarcoma, hepatocellular carcinoma and related tumors, alongside additional oncology programs.
BiotechDeep TechHealthtech
Founders & leadership
LH
Lan HuangPh.D.
Investors · 1
Frequently asked questions
- What does Seed Tx do?
- SEED Therapeutics develops de novo molecular glue degraders for targeted protein degradation, using its RITE3 platform to match E3 ligases with disease-causing target proteins. Its lead RBM39 degrader (ST-01156) is in Phase 1 trials for Ewing sarcoma, hepatocellular carcinoma and related tumors, alongside additional oncology programs.
- Who founded Seed Tx?
- Seed Tx was founded by Lan Huang.
- Who are Seed Tx's investors?
- Seed Tx's investors include Eisai Innovation, Inc..